Breaking News, Financial News

Financial Report: Roche

Oncology drugs fuel growth

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Financial Report: Roche 4Q13 4Q Revenues: 11.9 billion CHF (+7%) 4Q Earnings: not reported FY Revenues: 46.8 billion CHF (+3%) FY Earnings: 11.4 billion CHF (+18%) Comments: Pharma sales rose 3% to 36.3 billion CHF in 2013, hampered 4% by a strong Swiss franc. For the full year, Oncology products led the growth trend, with breast cancer drugs up 14% to 6.6 billion CHF (at CER). Avastin sales grew 13% to 6.3 billion CHF, while Rituxan revenues were up 6% to 7.0 billion CHF. Lucentis revenues...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters